MedDRA preferred term

Atrioventricular block complete: adverse event reports recording this term

6,565 reports to FDA record it, 2004–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

6,565
reports recording the term: 0% of all reports; 356
reports, 12 months to June 2026: 419 in the 12 months before; 99.7%
marked serious by the reporter: 57.4% across all reports; 13%
record death among outcomes, as reported: 9.1% across all reports

6,565 reports in FDA's adverse event database record the MedDRA term "Atrioventricular block complete": 0% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

356 reports recorded it in the 12 months to June 2026, down 15% from 419 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 99.7% are marked serious, 13% include death among the outcomes and 68.7% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Bisoprolol, Digoxin and Metoprolol. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Bisoprolol	beta-Adrenergic blocker	272	1.2%
Digoxin	Cardiac glycoside	244	1.5%
Metoprolol	beta-Adrenergic blocker	176	0.6%
Amlodipine	Calcium channel blocker	166	0.3%
Verapamil	—	161	2.1%
Avandia	—	155	0.2%
Diltiazem	—	148	1.4%
Atenolol	beta-Adrenergic blocker	140	0.8%
Rituximab	CD20-directed cytolytic antibody	113	0.1%
Methylprednisolone	Corticosteroid	98	0.2%
Furosemide	Loop diuretic	97	0.2%
Spironolactone	Aldosterone antagonist	97	0.5%
Enalapril	Angiotensin converting enzyme inhibitor	95	1.4%
Amiodarone	—	86	0.5%
Lacosamide	—	84	0.6%
Fosamax	Bisphosphonate	83	0.2%
Omeprazole	Proton pump inhibitor	83	0.1%
Prednisone	Corticosteroid	83	0%
Sulfasalazine	Aminosalicylate	83	0.2%
Lipitor	HMG-CoA reductase inhibitor	80	0.1%
Vimpat	—	80	0.7%
Carvedilol	alpha-Adrenergic blocker	79	0.6%
Verapamil hydrochloride	Calcium channel blocker	77	3%
Metformin	Biguanide	76	0.1%
Vioxx	—	73	0.2%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
beta-Adrenergic blocker	849	0.6%	0.2%
Corticosteroid	325	0%	0%
Calcium channel blocker	312	0.4%	0.4%
Programmed death Receptor-1 blocking antibody	285	0.1%	0.1%
Cardiac glycoside	248	1.5%	0.9%
Proton pump inhibitor	218	0%	0%
Angiotensin 2 receptor blocker	196	0.1%	0%
Serotonin reuptake inhibitor	195	0.1%	0%
Angiotensin converting enzyme inhibitor	191	0.2%	0.1%
HMG-CoA reductase inhibitor	169	0.1%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.5%33

2 to 110.7%46

12 to 171.8%119

18 to 448.2%541

45 to 6420.5%1,347

65 to 7420.7%1,360

75 and over29.6%1,945

Age not given17.9%1,174

Patient sex

Female44%2,891

Male46.6%3,058

Not given9.4%616

Grey bar: all 20,646,523 reports in the database. 32.8% of these reports give the United States as the country.

Questions about "Atrioventricular block complete"

What does "Atrioventricular block complete" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record atrioventricular block complete?

6,565 reports through June 2026 (0% of all reports), 356 of them in the latest 12 months.

Which drugs appear most often in these reports?

Bisoprolol (272), Digoxin (244), Metoprolol (176), Amlodipine (166) and Verapamil (161). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.